EpilepsyGTx
PrivateLast Round
Series A
Dec 10, 2025
Total Funding Raised
$43M
Momentum Score
75 /100
Company Overview
EpilepsyGTx is a biotechnology company developing cutting-edge gene therapies to treat refractory epilepsy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EpilepsyGTx Comps
Public and private peers based on sector, stage, and business model.
EpilepsyGTx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 10, 2025 | ||||
| Seed | Jun 24, 2024 |
EpilepsyGTx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| XGEN Venture | Series A |
| British Business Bank | Series A |
| Health Technology Holding | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 29, 2026
Professor Dimitri Kullmann appointed as the new CSO.
EpilepsyGTx Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about EpilepsyGTx's valuation, stock price, and market status.
